Abstract:Background: Elucidation of the mechanism of ubiquitation has led to novel ways to treat glioblastoma (GBM). A tripartite motif (TRIM) protein mediates a reversible, stringent ubiquitation which is closely related to glioma malignancy. This study intends to screen the most vital and abnormal regulating component of the tripartite motif protein and to explore its underlying mechanisms. Methods: TRIM21 is identified as an important oncogene that accelerates the progression of glioma cell through database in a multidimensional way and this is confirmed in human samples and cells. Tandem Mass Tags (TMT) and MS analysis are performed to discover the substrates of TRIM21.The underlying mechanisms are further investigated by CO-IP, luciferase reporter assays and gain and loss of function assays. In vivo treatment with siRNA is applied to evaluate the therapeutic significance of TRIM21. Result: We screened a panel of TRIM proteins and identified TRIM21, a E3 ubiquitin-protein ligase and autoantigen, as well as a prognostic biomarker for GBM. Functionally, high expression of wild-type TRIM21 accelerates tumor progression in vitro and in vivo, whereas TRIM21 mutants, including one with a critical RING-finger deletion, do not. Mechanistically, TRIM21 stimulates K63-linked ubiquitination and subcellular translocation of active β-catenin from the cytoplasm to the nucleus. Moreover, TRIM21 forms a complex with the β-catenin upstream regulator, TIF1γ, in the nucleus and accelerated its degradation by inducing K48-linked ubiquitination at K5 site, consequently increasing further nuclear β-catenin presence. Endogenous TRIM21 levels are found to be inversely correlated with TIF1γ but positively correlated with β-catenin in glioma tissue microarray experiments. Furthermore, direct injection of TRIM21 small interfering RNA (siRNA) into U87 cell-derived tumors (in vivo treatment with siRNA) is proved to inhibit tumor growth in nude mice. Conclusion: This work suggests that TRIM21/TIF1γ/β-catenin axis is involved in the progression of human GBM. TRIM21 is a promising therapeutic and prognostic biomarker for glioma with hyperactive β-catenin.

TTDA inhibited apoptosis by regulating the p53-Bax/Bcl2 axis in glioma

Dnmt1 Mediates Chemosensitivity By Reducing Methylation Of Mirna-20a Promoter In Glioma Cells

Molecular cloning and characterization of a novel human BTB domain-containing gene, , which is down-regulated in glioma

Thioridazine Enhances P62-Mediated Autophagy and Apoptosis Through Wnt/β-Catenin Signaling Pathway in Glioma Cells

TDP-43/HDAC6 axis promoted tumor progression and regulated nutrient deprivation-induced autophagy in glioblastoma

TBX15 facilitates malignant progression of glioma by transcriptional activation of TXDNC5

TNC Upregulation Promotes Glioma Tumourigenesis Through TDG-mediated Active DNA Demethylation

TRIP4 transcriptionally activates DDIT4 and subsequent mTOR signaling to promote glioma progression

LncRNA TUG1 acts as a tumor suppressor in human glioma by promoting cell apoptosis

Triphlorethol‐A attenuates U251 human glioma cancer cell proliferation and ameliorates apoptosis through JAK2/STAT3 and p38 MAPK/ERK signaling pathways

Knockdown of TRIM32 inhibits tumor growth and increases the therapeutic sensitivity to temozolomide in glioma in a p53-dependent and -independent manner

E3 ubiquitin ligase TRIM21 targets TIF1γ to regulate β-catenin signaling in glioblastoma

A Key Role of DNA Damage-Inducible Transcript 4 (DDIT4) Connects Autophagy and GLUT3-Mediated Stemness To Desensitize Temozolomide Efficacy in Glioblastomas

Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas

CARD16 restores tumorigenesis and restraints apoptosis in glioma cells Via FOXO1/TRAIL axis

TUBB4A Inhibits Glioma Development by Regulating ROS-PINK1/Parkin-Mitophagy Pathway

A Novel Gene, TARDBP, and the Protein It Encodes Can Predict Glioma Patient Prognosis and Establish a Prediction Model.

Triptolide induces apoptosis of glioma cells by inhibiting NF-κB activation during oxidative stress

Identification and Validation of TEAD Family's Prognostic Effects and Immune Microenvironment Regulations in Glioma

DHFR/TYMS Are Positive Regulators of Glioma Cell Growth and Modulate Chemo-Sensitivity to Temozolomide.

The overexpression and clinical significance of TBX15 in human gliomas